Alamar Biosciences Inc. announced that it has entered into aresearch development agreement with Pfizer Inc.'s Roerigdivision to develop an in vitro anti-fungal susceptibility testkit.

Using Alamar's proprietary Redox colorimetric reductionmethod, the partnership will develop a test kit to determinewhich medication and what dosage will be effective in treatingyeast infections, a condition affecting more than 5 millionpeople annually in the U.S. No such diagnostic kit iscommercially available yet.

Under the terms of the deal, Alamar of Sacramento, Calif., willreceive payments from Roerig and retain exclusive rights toany product that may be developed under the agreement.

(c) 1997 American Health Consultants. All rights reserved.